The global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is projected to reach USD 2,517 million by 2032, up from USD 1,413 million in 2022, growing at a CAGR of 6.1% during the forecast period from 2022 to 2032. This growth is driven by several key factors, including increasing awareness of AATD, advancements in genetic testing and personalized medicine, and the development of new, more effective therapies. The market is also benefiting from growing investment in research and development and the expansion of treatment options into emerging markets.
Challenges in the market include the high cost of treatment, limited access to therapy in some regions, and stringent regulatory requirements. Despite these challenges, there have been significant developments, such as the approval of new formulations like Prolastin-C Liquid by Grifols and the launch of Zemaira by CSL Behring in Japan. The increasing prevalence of respiratory disorders and genetic testing advancements further support market growth.
The hospital segment remains the dominant distribution channel, though specialty clinics and pharmacies are gaining market share due to their accessibility and convenience. Overall, the AATD augmentation therapy market is poised for significant growth, driven by technological advancements, increased awareness, and strategic collaborations among market players.
Key Takeaways
- The global AATD Augmentation Therapy market will reach USD 2,517 million by 2032, growing at a CAGR of 6.1%.
- Recent advancements in genetic disease diagnostic tools have improved AATD diagnosis and treatment outcomes.
- Prolastin C and Glassia are the leading products in AATD therapy, with Prolastin C having the largest market share.
- Hospitals are the primary end-users of AATD therapy due to the prevalence of genetic and respiratory disorders.
- The market is driven by genetic disorders, respiratory diseases, therapy effectiveness, and advancements in diagnostics.
- AATD augmentation therapy is not a cure, and improper administration can cause vein damage, restraining market growth.
- Opportunities in the market include using AAT from healthy donors, raising awareness, technological advancements, and government support.
- Over 80 AATD molecules are in clinical trials, driving innovation and market dynamics.
- North America dominates the market due to high awareness, government support, and advanced diagnostics.
- Asia Pacific is experiencing significant market growth in AATD augmentation therapy.
- North America and Europe hold substantial market shares, with North America registering USD 579.5 million in 2022 due to disease prevalence and key companies.
Get Sample PDF Report: https://market.us/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-market/request-sample/
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Key Segments
Based on Product Type
- Prolastin C
- Aralast NP
- Glassia
- Zemaira/Respreeza
Based on End-User
- Hospitals
- Specialty Clinics
- Pharmacies
Key Regions
- North America (The US, Canada, Mexico)
- Western Europe (Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, Rest of Western Europe)
- Eastern Europe (Russia, Poland, The Czech Republic, Greece, Rest of Eastern Europe)
- APAC (China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Rest of APAC)
- Latin America (Brazil, Colombia, Chile, Argentina, Costa Rica, Rest of Latin America)
- Middle East & Africa (Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, Rest of MEA)
Buy Directly: https://market.us/purchase-report/?report_id=95351
Key Players Analysis
Grifols is a leading global healthcare company based in Barcelona, Spain, known for its innovative plasma-derived medicines. In the Alpha-1 Antitrypsin Deficiency (AATD) augmentation therapy sector, Grifols offers PROLASTIN-C Liquid, a widely prescribed treatment. PROLASTIN-C helps increase alpha-1 protein levels in patients, providing long-term augmentation therapy for severe AATD cases. Recently, Grifols introduced new vial sizes to enhance dosing flexibility. They are also advancing subcutaneous delivery methods, potentially allowing patients to administer treatment at home, improving convenience and adherence.
Kamada Pharmaceuticals, based in Israel, specializes in plasma-derived protein therapeutics. Their flagship product for Alpha-1 Antitrypsin Deficiency is GLASSIA, an intravenous AAT augmentation therapy. GLASSIA is notable for being the first FDA-approved liquid, ready-to-use AAT treatment, simplifying administration for patients and healthcare providers. Kamada continues to invest in research to improve treatment outcomes and expand its portfolio of products for AATD and other rare diseases.
CSL Limited, headquartered in Australia, is a prominent biopharmaceutical company with a strong presence in the AATD augmentation therapy market. Their product, Zemaira, is an AAT augmentation therapy designed for chronic replacement therapy in adults with AAT deficiency. CSL Behring, a subsidiary of CSL Limited, focuses on developing and distributing innovative therapies to treat serious and rare diseases, including efforts to improve the safety and efficacy of AATD treatments.
Takeda Pharmaceutical, a global biopharmaceutical leader based in Japan, offers ALPHA-1 PROTEINASE INHIBITOR as part of its AATD augmentation therapy portfolio. The company emphasizes innovation and patient-centered care, aiming to provide high-quality therapies for rare diseases. Takeda’s commitment to enhancing the lives of patients with AATD is reflected in their ongoing research and development efforts, striving to bring more effective and convenient treatment options to the market.
Teva Pharmaceutical Industries, an Israeli multinational, is involved in the AATD augmentation therapy sector through its production of various generic and branded medications. Although Teva is better known for its extensive range of generic drugs, it also focuses on specialty treatments for rare diseases, including AATD. Their commitment to increasing accessibility and affordability of essential therapies helps address the needs of AATD patients globally.
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Key Players:
- Grifols S.A. (Spain)
- Kamada Pharmaceuticals
- CSL Limited
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries ltd.
- GlaxoSmithKline PLC
- Arrowhead Pharmaceutical Inc.
- LFB Biomedicaments S.A.
- Mereo BioPharma Group plc
- Intellia Therapeutics Inc.
- Inhibrx Inc.
- Centessa Pharmaceuticals (Z factor)
- Krystal Biotech
- Beam Therapeutics
- LOGICBIO THERAPEUTICS INC.
- Apic Bio
- Pfizer Inc.
- Other Key Players
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report Scope >> Market Value (2022): USD 1,413 Million || Forecast Revenue (2032): USD 2,517 Million || CAGR (2023-2032): 6.1% || Base Year Estimation: 2023 || Historic Period: 2019-2022 || Forecast Period: 2024-2033.
Inquire More about report: https://market.us/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-market/#inquiry
About Market.US
Market.US is renowned for its comprehensive market research and analysis, providing customized and syndicated reports to a global clientele. Specializing in a variety of sectors, they offer strategic insights and detailed market forecasts, assisting businesses in making informed decisions. With a focus on innovation and accuracy, Market.US supports clients in over 126 countries, and maintains a strong repeat customer rate, underscoring their commitment to quality and client satisfaction. Their team excels in delivering exceptional research services, ensuring that no detail is overlooked in any target market.
Contact Details
Market.us (Powered By Prudour Pvt. Ltd.)
Contact No: +1 718 618 4351.
Email: [email protected]
Blog: https://medicalmarketreport.com/
View More Trending Reports
AI In Life Science Market at USD 11.38 Billion by 2033
Antacids Market to Witness Significant Growth, Forecasted Value Reaches USD 10.2 Billion by 2033
Allogeneic Cell Therapy Devices Market Flourishes, Expected to Reach USD 3422.6 Million by 2033
Hepatitis D Market Emerges: Forecast Values Reach USD 1.0 Billion by 2033
Lung Disease Therapeutics Market Soars to USD 163.1 Billion by 2033